Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
23 February 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES | ||||
1. Identity of the issuer or the underlying issuer | Mediclinic International plc | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | x | |||
An acquisition or disposal of qualifying financial instruments whichmay result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | ||||
3. Full name of person(s) subject to the | Coronation Asset Management (Pty) Ltd | |||
4. Full name of shareholder(s) (if different from 3.): | N/A | |||
5. Date of the transaction and date on | 23 February 2017 | |||
6. Date on which issuer notified: | 23 February 2017 | |||
7. Threshold(s) that is/are crossed or | 3% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type of
if possible using |
Situation previous | Resulting situation after the triggering transaction | ||||||||||||||
Number |
Number |
Number |
Number of voting | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
GB00B8HX8Z88 | 21 606 841 | 21 606 841 | 22 794 561 | 22 794 561 | 3.09% | |||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financial | Exercise price | Expiration date |
Exercise/ | Number of voting rights instrument refers to | % of voting rights | |||||||||||
Nominal | Delta | |||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
22 794 561 | 3.09% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the | ||||||||||||||||
Proxy Voting: | ||||||||||||||||
10. Name of the proxy holder: | Coronation Asset Management (Pty) Ltd | |||||||||||||||
11. Number of voting rights proxy holder will cease | ||||||||||||||||
12. Date on which proxy holder will cease to hold | ||||||||||||||||
13. Additional information: | ||||||||||||||||
14. Contact name: | Jamie Rowland | |||||||||||||||
15. Contact telephone number: | +27 21 680 2000 | |||||||||||||||
Mediclinic's primary listing is on the Main Market of the LSE, with secondary listings on the JSE in South Africa and on the NSX in Namibia.
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website:www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
For further information please contact:
Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600
Mediclinic International plc published this content on 23 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 23 February 2017 14:07:18 UTC.
Original documenthttp://ir.mediclinic.com/phoenix.zhtml?c=145797&p=irol-rnsArticle&ID=2248756
Public permalinkhttp://www.publicnow.com/view/F25D253555BEF04C1FBD4842EFD6BC04398EF9FD